Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $2.9 million.

  • Heron Therapeutics' Share-based Compensation rose 477.59% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.5 million, marking a year-over-year decrease of 3025.82%. This contributed to the annual value of $13.0 million for FY2024, which is 6054.67% down from last year.
  • Latest data reveals that Heron Therapeutics reported Share-based Compensation of $2.9 million as of Q3 2025, which was up 477.59% from $2.8 million recorded in Q2 2025.
  • Heron Therapeutics' 5-year Share-based Compensation high stood at $13.9 million for Q2 2023, and its period low was $2.3 million during Q4 2024.
  • For the 5-year period, Heron Therapeutics' Share-based Compensation averaged around $7.6 million, with its median value being $7.9 million (2023).
  • As far as peak fluctuations go, Heron Therapeutics' Share-based Compensation soared by 3426.06% in 2023, and later crashed by 6712.23% in 2024.
  • Heron Therapeutics' Share-based Compensation (Quarter) stood at $12.9 million in 2021, then fell by 18.42% to $10.5 million in 2022, then tumbled by 58.87% to $4.3 million in 2023, then tumbled by 46.92% to $2.3 million in 2024, then increased by 24.27% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $2.8 million for Q2 2025, and $2.5 million during Q1 2025.